Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
Noosa News16 hours agoElectrify your vehicle, home or business at Noosa’s EV & Electrify Everything Expo
-
General22 hours agoElon Musk deletes post claiming Donald Trump is ‘in the Epstein files’
-
General20 hours agoVance downplays row between Trump, ’emotional guy’ Musk
-
General12 hours agoCanberra man accused of flashing and assaulting 12-year-old girl released on bail